For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 23,276 | |||
| General and administrative | 19,875 | |||
| Impairment of long-lived assets | 6,145 | |||
| Loss from operations | -49,296 | |||
| Other income (expense), net | 3,774 | |||
| Net loss | -45,522 | |||
| Unrealized gain (loss) on marketable securities | -8 | |||
| Comprehensive loss | -45,530 | |||
| Basic EPS | -14.35 | |||
| Diluted EPS | -14.35 | |||
| Basic Average Shares | 3,172,870 | |||
| Diluted Average Shares | 3,172,870 | |||
Passage BIO, Inc. (PASG)
Passage BIO, Inc. (PASG)